DISORDERS IN HEMOSTASIS SYSTEM AND PROBLEM OF THROMBOSES IN PATIENTS ON HEMODIALYSIS
https://doi.org/10.24884/1561-6274-2003-7-2-21-25
Abstract
Disorders in hemostasis system and problem of thromboses in patients on hemodialysis.
About the Authors
Yu. S. Mikheeva
Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова;
Республиканская больница г. Петрозаводска
Russian Federation
Russian Federation
S. H. Rumyantseva
Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова;
Республиканская больница г. Петрозаводска
Russian Federation
Russian Federation
A. M. Essaian
Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова;
Республиканская больница г. Петрозаводска
Russian Federation
Russian Federation
References
1. Баркаган З.С. Геморрагические заболевания и синдромы. М.: Медицина, 1988. -528 с.
2. Зубаиров Д.М. Тромбофилия//Казанский медицинский журнал. -1996. -Т. 77. -Ng 1. -С. 1 -5.
3. Ильин А.П., Богоявленский В.Ф. Тромбофилия при гемодиализе у больных хронической почечной недостаточностью и ее фраксипаринопрофилактика и терапия. Пособие для врачей. Ульяновск-Казань: Корпорация технологий продвижения, 2001. -33 с.
4. Константинов Ю.В., Гуревич К.Я., Абдурахимов С.М. Оценка адекватности хронического гемодиализа. Пособие для врачей. Санкт-Петербург: ТНЛ, 1999, 52 с.
5. Лопаткин H.A., Румянцев В.Б., Букаев Ю.Н., Голованов С.А. Синдром диссеминированного внутрисосудистого свертывания крови при урологических заболеваниях//Урология и нефрология. -1997. -№ 3. -с. 3-8.
6. Мачабели М.С. Коагулопатические синдромы. М.: Медицина, 1970. -304 с.
7. Неймарк М.И. Нарушения гемокоагуляции и фибринолиза у больных хронической почечной недостаточностью в процессе лечения гемодиализом и пути их коррекции//Тер. архив. -1984. -Ns 7. -с. 48-53.
8. О состоянии заместительной терапии хронической почечной недостаточности в Российской Федерации в 1999 году (Ежегодный отчет по данным Российского регистра)//Нефрология и диализ. -2000. -Т. 2, Ng 4. -С. 204-224.
9. Шутов Е.В.//Вопросы медицинской химии. -1994. -Ng 1.-с. 32-35.
10. Acevedo М., Pearce GL, Kottke-Marchant K., Sprecher DL Elevated fibrinogen and homocysteine levels enhance the risk of mortality in patients from a high-risk preventive cardiology clinic//Arterioscler Thromb Vasc Biol. -2002. -Vol. 22. -Ns 6. -P. 1042-1045.
11. Adler S., Szczech L., Qureshi A. et al. IgM anticardiolipin antibodies are associated with stenosis of vascular access in hemodialysis patients but do not predict thrombosis//Clin Nephrol. -2001. -Vol. 56, № 6. -P. 428-434.
12. Aken BE, Reitsma PH, Rosendaal FR Interleukin 8 and venous thrombosis: evidence for a role of inflammation in thrombosis//Br J Haematol. -2002. -Vol. 116, Ns 1. -P. 173-177.
13. Alwakeel J., Gader AM, Hurieb S. et al. Coagulation inhibitors and fibrinolytic parameters in patients on peritoneal dialysis and haemodialysis//Int UroI Nephrol. -1996. -Vol. 28. -Ns 2. -P. 255-261.
14. Ambuhl PM, Wuthrich RP, Korte W. et al. Plasma hypercoagulability in haemodialysis patients: impact of dialysis and anticoagulation//Nephrol Dial Transplant. -1997. -Vol. 12, Ns 11.-P. 2355-2364.
15. Assouad M., Eknoyan G. Does the choice of renal replacement therapy adversely affect the hypercoagulability associated with renal disease?//Am J Nephrol. -1998. -Vol. 18, Ns 3. -P. 175-178.
16. Bartels PC, Schoorl M., Schoorl M. et al. Activation of coagulation during treatment with haemodialysis//Scand J Clin Lab Invest. -2000. -Vol. 60, Ns 4. -P. 283-290.
17. Bertoli SV, di Belgiojoso GB1 Trezzi M. et al. Reduced blood levels of coagulation inhibitors in chronic hemodialysis compared with CAPD//Adv Perit Dial. -1995. -Vol. 11. -P. 127-ISO.
18. Billion S., Tribout B., Cadet E. et al. Hyperhomocysteinemia, folate and vitamin B12 in unsupplemented haemodialysis patients: effect of oral therapy with folic acid and vitamin BI 2//Nephrol Dial Transplant. -2002. -Vol. 17, Ns 3. -P. 455-461.
19. Blavy G., Kouame C. Renal pathology in the Ivory Coast: exploration and functional act of antithrombin III//Nephrologie. -1994. -Vol. 15. -№ 6. -P. 387-389.
20. Burke AP, Tracy RP, Kolodgie F. et al. Elevated C-reactive protein values and atherosclerosis in sudden coronary death: association with different pathologies//Circulation. -2002. -Vol. 105, № 17. -P. 2019-2023.
21. Casserly LF, Reddy SM, Dember LM Venous thromboembolism in end-stage renal disease//Am J Kidney Dis. -2000. -Vol. 36, № 2. -P. 405-411.
22. Clyne N., Lins LE, Egberg N. Long-term effects of erythropoietin treatment on the coagulation system during standardized hemodialysis//Clin nephrol. -1995. -Vol. 43, №4. -P. 260-267.
23. Coli L., Cianciolo G., Feliciangeli G. etal. Anticoagulation and platelet activation in hemodialysis: clinical results with PMMA//Contrib Hephrol. -1999. -Vol. 125. -P. 111-119.
24. De Vecchi AF, Bamonti-Catena F., Finazzi S. et al. Homocysteine, vitamin BI2, serum and erythrocyte folate in peritoneal dialysis patients//Clin Nephrol. -2001. -Vol. 55, N 4.-P. 313-317.
25. Franc RD, Weber J., Dresbach H. et al. Role of contact system activation in hemodialyzer-induced thrombogenicity//Kidney Int. -2001. -Vol. 60, № 5. -P. 1972-1981.
26. Hofbauer R., Moser D., Frass M. et al. Effect of anticoagulation on blood membrane interactions during hemodialysis//Kidney Int. -1999. -Vol. 56, № 4. -P. 1578-1583.
27. Inoue A., Wada H., Takagi M. et al. Hemostatic abnormalities in patients with thrombotic complications on maintenance hemodialysis//Clin Appl Thromb Hemost. -2000. -Vol. 6, № 2. -P. 100-103.
28. Jaar B., Denis A., Viron B. et al. Effects of long-term treatment with recombinant human erythropoietin on physiologic inhibitors of coagulation//Am J Nephrol. -1997. -Vol. 17, № 5. -P. 399-405.
29. Kim SB, Lee SK1 Park JS et al. Effects of fixed low-dose warfarin on hemostatic factors in continuous ambulatory peritoneal dialysis patients//Am J Kidney Dis. -2001. -Vol. 37, № 2. -P. 343-347.
30. Kobayashi M., Yorioka N., Yamakido M. Hypercoagulability and secondary hyperfibrinolysis may be related to abnormal lipid metabolism in patients treated with continuous ambulatory peritoneal dialysis//Nephron. -1997. -Vol. 76, Ns 1. -P. 56-61.
31. Lai KN. Protein C, protein S and antithrombin III metabolism in dialysis patients//Int J Artif Organs. -1993. -Vol. 16, Ns 1. -P. 4-6.
32. LeSar CJ, Merrick HW, Smith MR. Thrombotic complications resulting from hypercoagulable states in chronic hemodialysis vascular access//J Am Coll Surg. -1999. -Vol. 189, Ns 1. -P. 73-79.
33. Malyszko J., Malyszko JS, Mysliwiec M. Comparison of hemostatic disturbances between patients on CAPD and patients on hemodialysis//Perit Dial Int. -2001. -Vol. 21, Ns 2. -P. 158-165.
34. Malyszko JS, Malyszko J., Pawlak K. et al. Importance of serotonergic mechanism in the thrombotic complications in hemodialyzed patients treated with erythropoietin//Nephron. -2000. -Vol. 84, № 4. -P. 305-311.
35. Manns B., Hyndman E., Burgess E. et al. Oral vitamin BI2 and high-dose folic acid in hemodialysis patients with hyper-homocysteinemia//Kidney Int. -2001. -Vol. 59, № 3. -P. 1103-1109.
36. Martinelli I., Bucciarelli P., Zighetti ML et al. Low risk of thrombosis in family members of patients with hyperhomocysteinaemia//Br J Haematol. -2002. -Vol. 117, Ns 3. -P. 709-711.
37. Miozzari M., Wahl C. D-dimers in hemodialysis patients//Nephron. -2001. -Vol. 88, Ns 3. -P. 278-279.
38. McGregor DO, Dellow WJ, Lever PM et al. Dimethylglycine accumulates in uremia and predicts elevated plasma homocysteine concentrations//Kidney Int. -2001. -Vol. 59,-Ns 6. -P 2267-2272.
39. Nahlawi M., Seshadri N., Boparai N. et al. Usefulness of plasma vitamin B(6), B(12), folate, homocysteine, and creatinine in predicting outcomes in heart transplant recipients//Am J Cardiol. -2002. -Vol. 89, № 7. -P. 834-837.
40. Nakamura T., Saioji K., Hiejima Y. et al. Methylenetetrahydrofolate reductase genotype, vitamin BI2, and folate influence plasma homocysteine in hemodialysis patients//Am J Kidney Dis. -2002. -Vol. 39, № 5. -P. 1032-1039.
41. Oda H., Ohno M., Ohashi H. Coagulation and fibrinolysis factors in dialysis patients with and without ischemic heart disease//Adv Perit Dial. -2000. -Vol. 16. -P. 152-155.
42. Opatrny KJr. Hemostasis disorders in chronic renal failure//Kidney Int Suppl. -1997. -Vol. 62. -P. S87-S89.
43. Sagedal S., Hartmann A., Sundstrom K. et al. Anticoagulation intensity sufficient for haemodialysis does not prevent activation of coagulation and platelets//Nephrol Dial Transplant. -2001. -Vol. 16, Ns 5. -P. 987-993.
44. Sands JJ, Nudo SA1 Moore KD1 Ortel TL. Antibodies to prothrombin, factor V, and beta2-glycoprotein I and vascular access thrombosis//ASAIO J. -2001. -Vol. 47, Ns 5. -P. 507-510.
45. Vaziri ND, Gonzales EC, Wang J., Said S. Blood coagulation, fibrinolytic, and inhibitory proteins In end-stage renal disease: effect of hemodialysis//Am J Kidney Dis. -1994. -Vol. 23, Ns 6. -P. 828-835.
46. Zee RY, Ridker PM. Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis//Atherosclerosis. -2002. -Vol. 162, № 1. -P. 217-219.
47. Zydlewski AW, Stothard DR, Van Der Pol B. et al. Is there a role for Chlamydia pneumoniae in hemodialysis vascular access thrombosis?//Am J Kidney Dis. -2000. -Vol. 36, Ns 6. -P. 1122-1125.
Review
For citations:
Mikheeva Yu.S., Rumyantseva S.H., Essaian A.M. DISORDERS IN HEMOSTASIS SYSTEM AND PROBLEM OF THROMBOSES IN PATIENTS ON HEMODIALYSIS. Nephrology (Saint-Petersburg). 2003;7(2):21-25. (In Russ.) https://doi.org/10.24884/1561-6274-2003-7-2-21-25
Views:
304
Email this article 